Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06927947 · ClinicalTrials.gov registry record · NA
Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
A NA study of Hereditary Neoplastic Syndrome and Hereditary Malignant Neoplasm, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT06927947 is a NA study of Hereditary Neoplastic Syndrome and Hereditary Malignant Neoplasm that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 500 participants, below the 9,850-participant average among 3 other Hereditary Neoplastic Syndrome trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06927947, a NA study of Hereditary Neoplastic Syndrome and Hereditary Malignant Neoplasm, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Communication Intervention
- OTHER Health Promotion and Education
- OTHER Informational Intervention
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06927947
The ClinicalTrials.gov registry entry for NCT06927947 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,850-participant average among 3 other Hereditary Neoplastic Syndrome trials with a reported enrollment target (95% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hereditary Neoplastic Syndrome appearing as the primary indexed condition, and to 4 interventions - of which Survey Administration is the first listed.
NCT06927947 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06927947 about?
NCT06927947 is a clinical study titled "Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes". This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that ...
What is the current status of trial NCT06927947?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2025-09-23. Estimated completion is 2026-09-30.
What conditions does trial NCT06927947 study?
This clinical trial studies the following conditions: Hereditary Neoplastic Syndrome, Hereditary Malignant Neoplasm.
What interventions are being tested in trial NCT06927947?
The interventions under investigation include: Survey Administration (OTHER), Communication Intervention (OTHER), Health Promotion and Education (OTHER), Informational Intervention (OTHER).
Who is sponsoring clinical trial NCT06927947?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06927947 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Neoplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.